Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

While ketamine has been used clinically over the past decades, it has only been recently
shown to be a promising therapy for treatment-resistant depression (TRD). However …

Objective To confirm the rapid onset anti-suicidal benefits of ketamine in the short term and
at six weeks, overall and according to diagnostic group. Design Prospective, double blind …

Background: More than 2% of the general population experience suicidal ideas each year
and a large number of them will attempt suicide. Evidence-based therapeutic options to …

Background Racemic ketamine and esketamine have demonstrated rapid antidepressant
effects. We aimed to review the efficacy and safety of racemic and esketamine for …

The emerging roles of ketamine and esketamine as effective rapid-acting antidepressants
hold promise for patients suffering from treatment-resistant depression and/or major …

Over the past two decades, ketamine has emerged as a novel effective and rapid-acting
antidepressant. While the vast majority of studies on ketamine have focused on its ability to …

Background In recent years, ketamine and esketamine treatment have demonstrated rapid
antidepressant effects in adults with treatment-resistant depression (TRD). Hitherto …

Eating disorders (EDs) are serious, life-threatening psychiatric conditions associated with
physical and psychosocial impairment, as well as high morbidity and mortality. Given the …

Résumé Contexte Le Réseau canadien pour les traitements de l'humeur et de l'anxiété
(CANMAT) a publié les dernières lignes directrices cliniques pour le traitement du trouble …